SCHEMBL167012

SCHEMBL167012

O=c1ncc2ncccc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATAD2 Q6PL18 1/20 0.56
DAO P14920 2/20 0.51
PARP1 P09874 3/20 0.41
PDE2A O00408 1/20 0.39
PDE6D O43924 1/20 0.39
PDE8A O60658 1/20 0.39
PDE5A O76074 1/20 0.39
PDE9A O76083 1/20 0.39
PDE8B O95263 1/20 0.39
PDE6A P16499 1/20 0.39
PDE6G P18545 1/20 0.39
PDE4A P27815 1/20 0.39
PDE6B P35913 1/20 0.39
PDE6C P51160 1/20 0.39
PDE1A P54750 1/20 0.39
PDE1B Q01064 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
PDE3B Q13370 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2898417 0.98 ATAD2 (0.54) ATAD2DAOPARP1PDE2APDE6D
SCHEMBL27791126 0.88 ATAD2 (0.46) ATAD2DAOPARP1PDE2APDE6D
Isoxazole SCHEMBL29144694 0.86 ATAD2 (0.44) ATAD2DAOPARP1PDE2APDE6D
Aminothiazole SCHEMBL29250377 0.84 ATAD2 (0.43) ATAD2DAOPARP1FGFR1KDM4E
Trifluoromethanesulfonic Acid SCHEMBL5258752 0.84 DAO (0.43) ATAD2DAOPARP1FGFR1KDM4E
Quinoline SCHEMBL18171691 0.79 ALDH1A1 (0.55) ATAD2DAOPARP1FGFR1ALDH1A1
SCHEMBL18035168 0.74 ATAD2 (0.35) ATAD2DAOPDE3BPDE3A
SCHEMBL29937409 0.74 ATAD2 (0.35) ATAD2DAOPDE3BPDE3A
SCHEMBL31042178 0.73 DAO (0.53) ATAD2DAOPARP1PDE2APDE6D
SCHEMBL586351 0.73 DAO (0.53) ATAD2DAOPARP1PDE2APDE6D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4363043-B1 COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS NOVOCURE GMBH (CH) 2026-04-22 EP claimed
EP-4653437-A2 NOVEL HETEROCYCLIC COMPOUNDS Innovo Therapeutics Inc. (KR) 2025-11-26 EP claimed
US-20250325572-A1 TREATMENTS FOR PAIN SEVENLESS THERAPEUTICS LTD (GB) 2025-10-23 US claimed
EP-4021901-B1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2025-09-24 EP claimed
EP-4598538-A1 NEW TREATMENTS FOR PAIN Sevenless Therapeutics Limited (GB) 2025-08-13 EP claimed
US-12338246-B2 Pyrazine derivative and application thereof in inhibiting SHP2 SUZHOU GENHOUSE PHARMACEUTICAL CO., LTD. (CN) 2025-06-24 US claimed
EP-4072546-B1 INHIBITORS OF KDM5A FOR USE IN TREATMENT OF IDIOPATHIC INFLAMMATORY MYOPATHIES UNIV ANTWERPEN (BE) 2025-02-19 EP claimed
CN-118084902-B 2-Aminothiazole pyrimidopyridone compound or pharmaceutically acceptable salt or stereoisomer, preparation method and application 赣南师范大学 2024-10-29 CN claimed
CN-118580239-A Pyrimidopyridone derivative PDE5 inhibitor and application thereof 常州亚邦制药有限公司 2024-09-03 CN claimed
WO-2024175999-A2 BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF DUNAD THERAPEUTICS LTD. (GB) 2024-08-29 WO claimed
CN-1252069-C 2-aryl-naphthyridin-4-ones as antitumor agents UNIV NORTH CAROLINA CHAPEL HILL (US) 2006-04-19 CN claimed
US-20050176957-A1 Process for the preparation of pyridopyrimidones SCIOS INC. 2005-08-11 US claimed
WO-2005065416-A2 PROCESS FOR THE PREPARATION OF PYRIDOPYRIMIDONES SCIOS INC. (US) 2005-07-21 WO claimed
US-20050107350-A1 Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith PHARMACIA CORPORATION (US) 2005-05-19 US claimed
CN-1309561-A Therapeutic agent for erectile dysfunction MOCHIDA PHARM CO LTD (JP) 2001-08-22 CN claimed
CN-1259947-A 2-aryl-naphthyridin-4-ones as antitumor agents UNIV NORTH CAROLINA CHAPEL HILL (US) 2000-07-12 CN claimed
US-6071930-A FOR INHIBITION OF MITOSIS OR TUMOR GROWTH THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2000-06-06 US claimed
EP-0992240-A1 THERAPEUTIC AGENT FOR ERECTION FAILURE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-04-12 EP claimed
EP-0971921-A1 2-ARYL-NAPHTHYRIDIN-4-ONES AS ANTITUMOR AGENTS The University of North Carolina at Chapel Hill (US) 2000-01-19 EP claimed
WO-1998039332-A1 2-ARYL-NAPHTHYRIDIN-4-ONES AS ANTITUMOR AGENTS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 1998-09-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12338246-B2 Pyrazine derivative and application thereof in inhibiting SHP2 PTPN5, PTPN1, PTPN7 ATAD2 3825/4885DAO 2469/4885PARP1 4845/4885
US-20250325572-A1 TREATMENTS FOR PAIN OPRL1, ACHE, OPRK1 ATAD2 4098/4885DAO 1724/4885PARP1 4453/4885
US-20050176957-A1 Process for the preparation of pyridopyrimidones PDXK, PNPO, AGPS ATAD2 721/4885DAO 465/4885PARP1 611/4885
US-20050107350-A1 Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith PTGS2, PTGES2, PTGS1 ATAD2 2265/4885DAO 1652/4885PARP1 3401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.